The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Cancer Immunotherapy by Targeting IDO1/TDO and Their Downstream Effectors
Open accessAbstract
The tryptophan (TRP) to kynurenine (KYN) metabolic pathway is now firmly established as a key regulator of innate and adaptive immunity. A plethora of preclinical models suggests that this immune tolerance pathway - driven by the key and rate-limiting enzymes indoleamine-2,3-dioxygenase and TRP-2,3-dioxygenase - is active in cancer immunity, autoimmunity, infection, transplant rejection, and allergy. Drugs targeting this pathway, specifically indoleamine-2,3-dioxygenase, are already in clinical trials with the aim at reverting cancer-induced immunosuppression. In the past years, there has been an increase in our understanding of the regulation and downstream mediators of TRP metabolism, such as the aryl hydrocarbon receptor as a receptor for KYN and kynurenic acid. This more detailed understanding will expand our opportunities to interfere with the pathway therapeutically on multiple levels. Here, we discuss the perspective of targeting TRP metabolism at these different levels based on reviewing recent insight into the regulation of TRP metabolism and its downstream effectors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zelante, T., Iannitti, R. G., Cunha, C., De Luca, A., Giovannini, G., Pieraccini, G., Zecchi, R., D’Angelo, C., Massi-Benedetti, C., Fallarino, F., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.08.003 · Cited by 2,614 · cited 1×
“TARGETING AHR: CHALLENGING A PROMISCUOUS RECEPTOR Several metabolites of TRP including photoproducts such as 6formylindolo-[3,2-b]carbazole (FICZ) (40), bacterial products such as indole-3-aldehyde, phenazines, and naphthoquinones (41, 42), and plant products such as indoles, flavonoids, and polyphenoles (43) have bee…”
BackgroundAn endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
Opitz, C. A., Litzenburger, U. M., Sahm, F., Ott, M., Tritschler, I., Trump, S., Schumacher, T., Jestaedt, L., Schrenk, D., Weller, M., et al. (2011) · Nature · doi:10.1038/nature10491 · Cited by 1,898
Self-citationControl of Treg and TH17 cell differentiation by the aryl hydrocarbon receptor
Quintana, F. J., Basso, A. S., Iglesias, A. H., Korn, T., Farez, M. F., Bettelli, E., Caccamo, M., Oukka, M., & Weiner, H. L. (2008) · Nature · doi:10.1038/nature06880 · Cited by 1,865
Inhibition of T Cell Proliferation by Macrophage Tryptophan Catabolism
Munn, D. H., Shafizadeh, E., Attwood, J. T., Bondarev, I., Pashine, A., & Mellor, A. L. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.9.1363 · Cited by 1,623
An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells
Mezrich, J. D., Fechner, J. H., Zhang, X., Johnson, B. P., Burlingham, W. J., & Bradfield, C. A. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903670 · Cited by 1,601
Regulation of Immune Responses by Prostaglandin E2
Kalinski, P. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1101029 · Cited by 1,474
Modulation of tryptophan catabolism by regulatory T cells
Fallarino, F., Grohmann, U., Hwang, K. W., Orabona, C., Vacca, C., Bianchi, R., Belladonna, M. L., Fioretti, M. C., Alegre, M.-L., & Puccetti, P. (2003) · Nature Immunology · doi:10.1038/ni1003 · Cited by 1,374
Munn, D. H., Sharma, M. D., Baban, B., Harding, H. P., Zhang, Y., Ron, D., & Mellor, A. L. (2005) · Immunity · doi:10.1016/j.immuni.2005.03.013 · Cited by 1,272
CTLA-4–Ig regulates tryptophan catabolism in vivo
Grohmann, U., Orabona, C., Fallarino, F., Vacca, C., Calcinaro, F., Falorni, A., Candeloro, P., Belladonna, M. L., Bianchi, R., Fioretti, M. C., et al. (2002) · Nature Immunology · doi:10.1038/ni846 · Cited by 1,161
Muller, A. J., DuHadaway, J. B., Donover, P. S., Sutanto-Ward, E., & Prendergast, G. C. (2005) · Nature Medicine · doi:10.1038/nm1196 · Cited by 1,064
Exogenous Stimuli Maintain Intraepithelial Lymphocytes via Aryl Hydrocarbon Receptor Activation
Li, Y., Innocentin, S., Withers, D. R., Roberts, N. A., Gallagher, A. R., Grigorieva, E. F., Wilhelm, C., & Veldhoen, M. (2011) · Cell · doi:10.1016/j.cell.2011.09.025 · Cited by 820
Sharma, M. D., Baban, B., Chandler, P., Hou, D.-Y., Singh, N., Yagita, H., Azuma, M., Blazar, B. R., Mellor, A. L., & Munn, D. H. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31911 · Cited by 792
Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells
Pallotta, M. T., Orabona, C., Volpi, C., Vacca, C., Belladonna, M. L., Bianchi, R., Servillo, G., Brunacci, C., Calvitti, M., Bicciato, S., et al. (2011) · Nature Immunology · doi:10.1038/ni.2077 · Cited by 703
Nguyen, N. T., Kimura, A., Nakahama, T., Chinen, I., Masuda, K., Nohara, K., Fujii-Kuriyama, Y., & Kishimoto, T. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014465107 · Cited by 685
Aryl hydrocarbon receptor control of a disease tolerance defence pathway
Bessede, A., Gargaro, M., Pallotta, M. T., Matino, D., Servillo, G., Brunacci, C., Bicciato, S., Mazza, E. M. C., Macchiarulo, A., Vacca, C., et al. (2014) · Nature · doi:10.1038/nature13323 · Cited by 674
Self-citationHolmgaard, R. B., Zamarin, D., Munn, D. H., Wolchok, J. D., & Allison, J. P. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130066 · Cited by 634
Hou, D.-Y., Muller, A. J., Sharma, M. D., DuHadaway, J., Banerjee, T., Johnson, M., Mellor, A. L., Prendergast, G. C., & Munn, D. H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2925 · Cited by 586
Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase
Pilotte, L., Larrieu, P., Stroobant, V., Colau, D., Dolušić, E., Frédérick, R., De Plaen, E., Uyttenhove, C., Wouters, J., Masereel, B., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113873109 · Cited by 572
Balachandran, V. P., Cavnar, M. J., Zeng, S., Bamboat, Z. M., Ocuin, L. M., Obaid, H., Sorenson, E. C., Popow, R., Ariyan, C., Rossi, F., et al. (2011) · Nature Medicine · doi:10.1038/nm.2438 · Cited by 521
Metz, R., DuHadaway, J. B., Kamasani, U., Laury-Kleintop, L., Muller, A. J., & Prendergast, G. C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1872 · Cited by 467
Munn, D. H., Sharma, M. D., & Mellor, A. L. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.7.4100 · Cited by 457
Haynes, B. F., Hemler, M. E., Mann, D. L., Eisenbarth, G. S., Shelhamer, J., Mostowski, H. S., Thomas, C. A., Strominger, J. L., & Fauci, A. S. (1981) · The Journal of Immunology · doi:10.4049/jimmunol.126.4.1409 · Cited by 450
The aryl hydrocarbon receptor in immunity
Esser, C., Rannug, A., & Stockinger, B. (2009) · Trends in Immunology · doi:10.1016/j.it.2009.06.005 · Cited by 447
STAT3 SIGNALING: Anticancer Strategies and Challenges
Johnston, P. A., & Grandis, J. R. (2011) · Molecular Interventions · doi:10.1124/mi.11.1.4 · Cited by 406
Metz, R., Rust, S., DuHadaway, J. B., Mautino, M. R., Munn, D. H., Vahanian, N. N., Link, C. J., & Prendergast, G. C. (2012) · OncoImmunology · doi:10.4161/onci.21716 · Cited by 384
AhR sensing of bacterial pigments regulates antibacterial defence
Moura-Alves, P., Faé, K., Houthuys, E., Dorhoi, A., Kreuchwig, A., Furkert, J., Barison, N., Diehl, A., Munder, A., Constant, P., et al. (2014) · Nature · doi:10.1038/nature13684 · Cited by 369
Immune escape as a fundamental trait of cancer: focus on IDO
Prendergast, G. C. (2008) · Oncogene · doi:10.1038/onc.2008.35 · Cited by 325
Litzenburger, U. M., Opitz, C. A., Sahm, F., Rauschenbach, K. J., Trump, S., Winter, M., Ott, M., Ochs, K., Lutz, C., Liu, X., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1637 · Cited by 322
Self-citationAryl hydrocarbon receptor signaling mediates expression of indoleamine 2,3-dioxygenase
Vogel, C. F. A., Goth, S. R., Dong, B., Pessah, I. N., & Matsumura, F. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.07.156 · Cited by 296
Complementation of dominant suppression implicates CD98 in integrin activation
Fenczik, C. A., Sethi, T., Ramos, J. W., Hughes, P. E., & Ginsberg, M. H. (1997) · Nature · doi:10.1038/36349 · Cited by 287
Kanai, M., Funakoshi, H., Takahashi, H., Hayakawa, T., Mizuno, S., Matsumoto, K., & Nakamura, T. (2009) · Molecular Brain · doi:10.1186/1756-6606-2-8 · Cited by 273
A Constitutively Active Dioxin/Aryl Hydrocarbon Receptor Promotes Hepatocarcinogenesis in Mice
Moennikes, O., Loeppen, S., Buchmann, A., Andersson, P., Ittrich, C., Poellinger, L., & Schwarz, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-0875 · Cited by 228
Wincent, E., Bengtsson, J., Bardbori, A. M., Alsberg, T., Luecke, S., Rannug, U., & Rannug, A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1118467109 · Cited by 217
Orabona, C., Pallotta, M. T., Volpi, C., Fallarino, F., Vacca, C., Bianchi, R., Belladonna, M. L., Fioretti, M. C., Grohmann, U., & Puccetti, P. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810278105 · Cited by 204
Dolušić, E., Larrieu, P., Moineaux, L., Stroobant, V., Pilotte, L., Colau, D., Pochet, L., Van den Eynde, B., Masereel, B., Wouters, J., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2006782 · Cited by 181
Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells
Lob, S., Konigsrainer, A., Schafer, R., Rammensee, H.-G., Opelz, G., & Terness, P. (2008) · Blood · doi:10.1182/blood-2007-10-116111 · Cited by 167
Opitz, C. A., Litzenburger, U. M., Opitz, U., Sahm, F., Ochs, K., Lutz, C., Wick, W., & Platten, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019823 · Cited by 159
Self-citationD’Angelo, S. P., Shoushtari, A. N., Keohan, M. L., Dickson, M. A., Gounder, M. M., Chi, P., Loo, J. K., Gaffney, L., Schneider, L., Patel, Z. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2349 · Cited by 138
Iversen, T. Z., Engell-Noerregaard, L., Ellebæk, E., Andersen, R. S., Larsen, S. K., Bjoern, J., Zeyher, C., Gouttefangeas, C., Thomsen, B. M., Holm, B., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1560 · Cited by 129
Nanosensor Detection of an Immunoregulatory Tryptophan Influx/Kynurenine Efflux Cycle
Kaper, T., Looger, L. L., Takanaga, H., Platten, M., Steinman, L., & Frommer, W. B. (2007) · PLoS Biology · doi:10.1371/journal.pbio.0050257 · Cited by 121
Self-citationSalter, M., Hazelwood, R., Pogson, C. I., Iyer, R., & Madge, D. J. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00006-l · Cited by 119
Meininger, D. P., Zalameda, L. P., Liu, Y., Stepan, L. P., Borges, L., McCarter, J. D., & Sutherland, C. L. (2011) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2011.07.023 · Cited by 117
A high-affinity, tryptophan-selective amino acid transport system in human macrophages
Seymour, R. L., Ganapathy, V., Mellor, A. L., & Munn, D. H. (2006) · Journal of Leukocyte Biology · doi:10.1189/jlb.1205727 · Cited by 69
Indoleamine 2,3-dioxygenase activity and l-tryptophan transport in human breast cancer cells
Travers, M. T., Gow, I. F., BARBER, M. C., Thomson, J., & SHENNAN, D. B. (2003) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2003.12.004 · Cited by 68
Antitumour agents as inhibitors of tryptophan 2,3-dioxygenase
Pantouris, G., & Mowat, C. G. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.11.037 · Cited by 62
Ott, M., Litzenburger, U. M., Rauschenbach, K. J., Bunse, L., Ochs, K., Sahm, F., Pusch, S., Opitz, C. A., Blaes, J., von Deimling, A., et al. (2014) · Glia · doi:10.1002/glia.22734 · Cited by 59
Self-citationKudo, Y., & Boyd, C. A. R. (2001) · The Journal of Physiology · doi:10.1111/j.1469-7793.2001.0417i.x · Cited by 58
Gibney, G. T., Hamid, O., Gangadhar, T. C., Lutzky, J., Olszanski, A. J., Gajewski, T. F., Chmielowski, B., Boasberg, P. D., Zhao, Y., Newton, R. C., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.3010 · Cited by 52
Lanzinger, M., Jürgens, B., Hainz, U., Dillinger, B., Raberger, J., Fuchs, D., & Heitger, A. (2012) · European Journal of Immunology · doi:10.1002/eji.201141765 · Cited by 23
A phase I study of indoximod in combination with docetaxel in metastatic solid tumors.
Jackson, E., Dees, E. C., Kauh, J. S. W., Harvey, R. D., Neuger, A. M., Lush, R. M., Antonia, S. J., Minton, S. E., Ismail-Khan, R. R., Han, H. S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.3026 · Cited by 22
A phase I study of 1-methyl-D-tryptophan in combination with docetaxel in metastatic solid tumors.
Jackson, E., Minton, S. E., Ismail-Khan, R. R., Han, H. S., Neuger, A. M., Antonia, S. J., Sullivan, D. M., & Soliman, H. H. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.tps2620 · Cited by 7
Cited by
Understanding the Intersections between Metabolism and Cancer Biology
Vander Heiden, M. G., & DeBerardinis, R. J. (2017) · Cell · doi:10.1016/j.cell.2016.12.039 · Cited by 2,293
Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond
Platten, M., Nollen, E. A. A., Röhrig, U. F., Fallarino, F., & Opitz, C. A. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0016-5 · Cited by 1,586
Mechanisms of resistance to immune checkpoint inhibitors
Jenkins, R. W., Barbie, D. A., & Flaherty, K. T. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.434 · Cited by 1,383
Melief, C. J. M., van Hall, T., Arens, R., Ossendorp, F., & van der Burg, S. H. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80009 · Cited by 1,164
Kynurenine pathway of tryptophan metabolism: regulatory and functional aspects
Badawy, A. A.-B. (2017) · International Journal of Tryptophan Research · doi:10.1177/1178646917691938 · Cited by 1,158
Metadata
- Authors
- Platten, M., von Knebel Doeberitz, N., Oezen, I., Wick, W., & Ochs, K.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2015-01-12
- Volume
- 5
- Pages
- 673-673
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2054475219
- Cited by
- 340
- References
- 51
- FWCI
- 10.26
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.